Market research
ETX.LSE e-therapeutics plc
LSE GBP Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 56M
- P/E ratio
- Not available
- Analyst target
- 10
- Dividend yield
- Not available
- Beta
- 0.46
Profile
Company facts
- Exchange
- LSE
- Currency
- GBP
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- GB00B2823H99
- Market cap
- 56M
- P/E ratio
- Not available
- Analyst target
- 10
- Dividend yield
- Not available
- Beta
- 0.46
About
About e-therapeutics plc
e-therapeutics plc engages in drug discovery research activities in the United Kingdom. It offers HepNet, a proprietary, hepatocyte-specific, and computational biology platform that addresses key limitations of the biopharmaceutical industry, including extracting value from big data, addressing complex diseases, and improving translatability in research and development; and GalOmic, a RNA interference (RNAi) chemistry platform, which enables the generation of GalNAc-conjugated short interfering RNA drug candidates for hepatocyte-specific gene silencing through RNAi of any target gene identified by HepNet. The company was incorporated in 2001 and is based in London, the United Kingdom.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ETX.LSE discussion.
5 years, 5 months ago
e-therapeutics plc is currently in a long term uptrend where the price is trading 3.2% above its 200 day moving average.
From a valuation standpoint, the stock is 44.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 246.2.
Based on the above factors, e-therapeutics plc gets an overall score of 2/5.